Table 2.
Serum lipid profile and atherogenic index.
| No. of days | Parameters | Control | D. Control | Std | EtOH 100 (mg kg−1) | EtOH 200 (mg kg−1) |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| TC (mg dl−1) | 54.02 ± 1.99 | 53.42 ± 3.66 | 55.84 ± 3.44 | 54.91 ± 4.50 | 54.38 ± 3.04 | |
| HDL (mg dl−1) | 31.69 ± 1.95 | 30.03 ± 1.15 | 29.47 ± 1.50 | 26.62 ± 1.88 | 30.62 ± 2.16 | |
| LDL (mg dl−1) | 7.50 ± 3.41 | 5.86 ± 3.89 | 10.93 ± 3.62 | 14.13 ± 4.54 | 9.64 ± 2.06 | |
| VLDL (mg dl−1) | 14.83 ± 0.73 | 17.53 ± 0.48 | 15.44 ± 0.77 | 14.16 ± 0.66 | 14.12 ± 0.82 | |
| TG (mg dl−1) | 74.15 ± 3.65 | 87.63 ± 2.42 | 77.18 ± 3.85 | 70.80 ± 3.31 | 70.62 ± 4.11 | |
| 14 days | ||||||
| TC (mg dl−1) | 63.63 ± 4.95 | 143.36 ± 8.01(a) | 71.82 ± 5.30(b) | 122.90 ± 8.18(a),(b),(c) | 108.76 ± 6.67(b),(c),(d) | |
| HDL (mg dl−1) | 35.13 ± 1.98 | 34.75 ± 4.27 | 38.25 ± 4.35 | 38.44 ± 1.62 | 40.50 ± 2.65 | |
| LDL (mg dl−1) | 7.09 ± 7.09 | 15.86 ± 12.92 | 6.14 ± 5.68 | 15.73 ± 4.36 | 13.69 ± 9.78 | |
| VLDL (mg dl−1) | 35.59 ± 1.66 | 92.75 ± 12.67(a) | 39.70 ± 1.62(b) | 68.73 ± 3.90(a),(b),(c) | 51.95 ± 5.70(a),(b),(d) | |
| TG (mg dl−1) | 177.93 ± 8.29 | 463.77 ± 63.37(a) | 198.50 ± 8.10(b) | 373.63 ± 19.48(a),(b),(c) | 299.76 ± 28.49(a),(b),(d) | |
| 36 days | ||||||
| TC (mg dl−1) | 254.86 ± 2.18 | 552.55 ± 42.00(a) | 269.83 ± 11.45(b) | 399.96 ± 41.61(a),(b),(c) | 359.65 ± 41.08(a),(b),(c) | |
| HDL (mg dl−1) | 33.94 ± 2.21 | 32.94 ± 3.56 | 38.00 ± 5.89 | 34.00 ± 4.40 | 37.91 ± 1.64 | |
| LDL (mg dl−1) | 170.49 ± 5.41 | 347.48 ± 32.80(a) | 175.53 ± 9.05(b) | 177.33 ± 39.96(b) | 208.64 ± 42.99(b) | |
| VLDL (mg dl−1) | 50.43 ± 6.57 | 172.13 ± 12.35(a) | 56.29 ± 1.79(b) | 138.63 ± 3.72(b) | 113.10 ± 6.71(a),(b),(c),(d) | |
| TG (mg dl−1) | 252.15 ± 32.84 | 860.65 ± 61.77(a) | 281.46 ± 8.96(b) | 663.16 ± 18.58(a),(b),(c) | 539.50 ± 33.55(a),(b),(c),(d) | |
| 72 days | ||||||
| TC (mg dl−1) | 353.78 ± 5.78 | 868.43 ± 47.98(a) | 384.69 ± 4.94(b) | 604.58 ± 27.42(a),(b),(c) | 543.47 ± 53.91(a),(b),(c),(d) | |
| HDL (mg dl−1) | 34.25 ± 1.71 | 30.00 ± 1.15 | 41.75 ± 4.92(b) | 35.25 ± 2.99 | 38.58 ± 4.38(b) | |
| LDL (mg dl−1) | 252.41 ± 7.47 | 582.44 ± 52.37(a) | 267.06 ± 2.23(b) | 489.17 ± 33.85(a),(b),(c) | 348.02 ± 63.85(a),(b),(d) | |
| VLDL (mg dl−1) | 67.11 ± 3.45 | 255.98 ± 7.82(a) | 75.88 ± 2.25(b) | 180.16 ± 13.48(a),(b),(c) | 156.87 ± 9.58(a),(b),(c),(d) | |
| TG (mg dl−1) | 335.57 ± 17.27 | 1279.92 ± 39.09(a) | 379.38 ± 11.23(b) | 900.79 ± 67.40(a),(b),(c) | 704.36 ± 47.92(a),(b),(c),(d) | |
| Atherogenic Index | 10.32 ± 2.38 | 28.94 ± 2.55 | 9.21 ± 1.02 | 19.98 ± 4.18 | 14.08 ± 3.31 |
Values expressed are mean ± SD of four animals per group.
(a),(b),(c),(d)statistical significance at P < .05 when compared with control, disease control, standard and treatment, respectively, on performing repeated measures ANOVA with Tukey's multiple comparison post hoc test.